Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas.

Babovic-Vuksanovic D, Widemann BC, Dombi E, Gillespie A, Wolters PL, Toledo-Tamula MA, O'Neill BP, Fox E, MacDonald T, Beck H, Packer RJ.

Pediatr Neurol. 2007 May;36(5):293-300.

PMID:
17509460
2.

Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Widemann BC, Babovic-Vuksanovic D, Dombi E, Wolters PL, Goldman S, Martin S, Goodwin A, Goodspeed W, Kieran MW, Cohen B, Blaney SM, King A, Solomon J, Patronas N, Balis FM, Fox E, Steinberg SM, Packer RJ.

Pediatr Blood Cancer. 2014 Sep;61(9):1598-602. doi: 10.1002/pbc.25041. Epub 2014 Apr 22.

PMID:
24753394
3.

Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.

Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D, Gillespie A, Whitcomb P, Palumbo JS, Pitney A, Jayaprakash N, Zannikos P, Balis FM.

J Clin Oncol. 2006 Jan 20;24(3):507-16.

PMID:
16421428
4.

Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.

Kim A, Dombi E, Tepas K, Fox E, Martin S, Wolters P, Balis FM, Jayaprakash N, Turkbey B, Muradyan N, Choyke PL, Reddy A, Korf B, Widemann BC.

Pediatr Blood Cancer. 2013 Mar;60(3):396-401. doi: 10.1002/pbc.24281. Epub 2012 Sep 7.

PMID:
22961690
5.

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC.

N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943.

6.

Phase II trial of pirfenidone in adults with neurofibromatosis type 1.

Babovic-Vuksanovic D, Ballman K, Michels V, McGrann P, Lindor N, King B, Camp J, Micic V, Babovic N, Carrero X, Spinner R, O'Neill B.

Neurology. 2006 Nov 28;67(10):1860-2. Epub 2006 Oct 11.

PMID:
17035676
7.

Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.

Kim A, Gillespie A, Dombi E, Goodwin A, Goodspeed W, Fox E, Balis FM, Widemann BC.

Neurology. 2009 Oct 20;73(16):1273-9. doi: 10.1212/WNL.0b013e3181bd1326.

8.

Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas.

Karmazyn B, Cohen MD, Jennings SG, Robertson KA.

Pediatr Radiol. 2012 Oct;42(10):1218-22. doi: 10.1007/s00247-012-2440-0. Epub 2012 Jun 22.

PMID:
22722872
9.

Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Widemann BC, Dombi E, Gillespie A, Wolters PL, Belasco J, Goldman S, Korf BR, Solomon J, Martin S, Salzer W, Fox E, Patronas N, Kieran MW, Perentesis JP, Reddy A, Wright JJ, Kim A, Steinberg SM, Balis FM.

Neuro Oncol. 2014 May;16(5):707-18. doi: 10.1093/neuonc/nou004. Epub 2014 Feb 4.

10.

Response of NF1-related plexiform neurofibroma to high-dose carboplatin.

Hummel T, Anyane-Yeboa A, Mo J, Towbin A, Weiss B.

Pediatr Blood Cancer. 2011 Mar;56(3):488-90. doi: 10.1002/pbc.22827. Epub 2010 Nov 11.

PMID:
21225936
11.

Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.

Robertson KA, Nalepa G, Yang FC, Bowers DC, Ho CY, Hutchins GD, Croop JM, Vik TA, Denne SC, Parada LF, Hingtgen CM, Walsh LE, Yu M, Pradhan KR, Edwards-Brown MK, Cohen MD, Fletcher JW, Travers JB, Staser KW, Lee MW, Sherman MR, Davis CJ, Miller LC, Ingram DA, Clapp DW.

Lancet Oncol. 2012 Dec;13(12):1218-24. doi: 10.1016/S1470-2045(12)70414-X. Epub 2012 Oct 23.

12.

Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas.

Jakacki RI, Dombi E, Steinberg SM, Goldman S, Kieran MW, Ullrich NJ, Pollack IF, Goodwin A, Manley PE, Fangusaro J, Allen R, Widemann BC.

Neuro Oncol. 2017 Feb 1;19(2):289-297. doi: 10.1093/neuonc/now158.

PMID:
27510726
13.

Interferon-α for unresectable progressive and symptomatic plexiform neurofibromas.

Kebudi R, Cakir FB, Gorgun O.

J Pediatr Hematol Oncol. 2013 Apr;35(3):e115-7. doi: 10.1097/MPH.0b013e318270cd24.

PMID:
23042022
14.

Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas.

Jakacki RI, Dombi E, Potter DM, Goldman S, Allen JC, Pollack IF, Widemann BC.

Neurology. 2011 Jan 18;76(3):265-72. doi: 10.1212/WNL.0b013e318207b031.

15.

Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.

Weiss B, Widemann BC, Wolters P, Dombi E, Vinks AA, Cantor A, Korf B, Perentesis J, Gutmann DH, Schorry E, Packer R, Fisher MJ.

Pediatr Blood Cancer. 2014 Jun;61(6):982-6.

PMID:
24851266
16.

NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.

Dombi E, Solomon J, Gillespie AJ, Fox E, Balis FM, Patronas N, Korf BR, Babovic-Vuksanovic D, Packer RJ, Belasco J, Goldman S, Jakacki R, Kieran M, Steinberg SM, Widemann BC.

Neurology. 2007 Feb 27;68(9):643-7. Epub 2007 Jan 10.

PMID:
17215493
17.

Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.

Weiss B, Widemann BC, Wolters P, Dombi E, Vinks A, Cantor A, Perentesis J, Schorry E, Ullrich N, Gutmann DH, Tonsgard J, Viskochil D, Korf B, Packer RJ, Fisher MJ.

Neuro Oncol. 2015 Apr;17(4):596-603. doi: 10.1093/neuonc/nou235. Epub 2014 Oct 14. Erratum in: Neuro Oncol. 2015 Jun;17(6):905.

18.

Experimental therapy for neurofibromatosis I shows promise: cancer drug shrinks some plexiform neuromas.

[No authors listed]

Am J Med Genet A. 2013 Feb;161A(2):viii-ix. doi: 10.1002/ajmg.a.35856. No abstract available.

PMID:
23348988
19.

Plexiform neurofibromas in NF1: toward biologic-based therapy.

Packer RJ, Gutmann DH, Rubenstein A, Viskochil D, Zimmerman RA, Vezina G, Small J, Korf B.

Neurology. 2002 May 28;58(10):1461-70. Review.

PMID:
12041525
20.

Growth behavior of plexiform neurofibromas after surgery.

Nguyen R, Ibrahim C, Friedrich RE, Westphal M, Schuhmann M, Mautner VF.

Genet Med. 2013 Sep;15(9):691-7. doi: 10.1038/gim.2013.30. Epub 2013 Apr 18.

PMID:
23598713

Supplemental Content

Support Center